publication date: Jul. 19, 2019

In Brief

Biden Cancer Initiative suspends operations

The Biden Cancer Initiative July 15 announced that it has suspended operations.

The nonprofit was built to continue the pursuit of the goals of the White House Cancer Moonshot program created by President Barack Obama and led by Vice President Joe Biden (The Cancer Letter, April 7, 2017).

The Biden Cancer Initiative was founded on June 26, 2017. Biden is pursuing the Democratic nomination for US Presidency.

“For more than two years, the Biden Cancer Initiative has focused on creating and implementing programs and platforms that accelerated progress against cancer,” Greg Simon, president of the Biden Cancer Initiative, said in a statement. “Today, we are suspending activities, given our unique circumstances.

“We remain personally committed to the cause, but at this time will have to pause efforts. We thank the community for their incredible response to our mission to improve the cancer journey for patients and to improve outcomes for all patients for generations to come.”

The Cancer Letter’s coverage of the Moonshot, which provided a new funding stream for NCI is posted here.


Callender named president and CEO of Memorial Hermann Health System

David Callender was named president and CEO of the Memorial Hermann Health System effective Sept. 1.

A surgeon who specializes in head and neck cancer, Collender has most recently served as president of the University of Texas Medical Branch (UTMB Health. He has held that job since 2007.

Callender’s selection was announced to the faculty and staff in a letter from Charles E. Stokes, the current president … Continue reading Biden Cancer Initiative suspends operations

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.